Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.

If you are wondering whether Moderna's share price still reflects its underlying worth, it helps to start with the recent share price performance and how it lines up with the current valuation checks.

LIBERTY is part of the Company’s broader REVOLUTION clinical program designed to elaborate the profile of monoclonal antibody-mediated ...

The company, however, continues to work on a phase 1/2 study of its H5 mRNA flu vaccine for pandemic preparedness.

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock could revive after a 91% fall from its peak.

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

mRNA-3927 is an investigational novel mRNA-based therapeutic agent that is composed of two mRNAs encoding for normal human ...